The landscape of breast cancer treatment has undergone a radical transformation over the last half-century. We have moved from the era of the disfiguring radical mastectomy to the more refined lumpectomy, and now, we stand on the precipice of a new "scarless" era. At the forefront of this shift is cryoablation—a technique that uses extreme cold to destroy malignant tissue without the need for traditional surgery.
Once reserved for skin cancers or cardiac arrhythmias, cryoablation is now emerging as a viable, FDA-approved alternative for specific breast cancer patients. Supported by the Breast Cancer Research Foundation (BCRF) and leading oncologists, this technology represents a significant step toward the "de-escalation" of cancer care: providing effective treatment while minimizing the physical and psychological trauma of invasive surgery.
Main Facts: The Science of Freezing Cancer
Cryoablation is a minimally invasive procedure that destroys a tumor by freezing it in situ. Unlike surgery, which involves cutting through healthy tissue to remove a mass, cryoablation uses a thin, needle-like probe (a cryoprobe) to deliver sub-zero temperatures directly into the heart of the tumor.
How the Procedure Works
The process is deceptively simple but biologically complex. Under the guidance of real-time ultrasound imaging, a physician inserts the cryoprobe through a tiny incision in the skin—usually so small it requires only a bandage rather than stitches. Once the probe is positioned within the tumor, liquid nitrogen or argon gas is circulated through the device.
This creates what oncologists call an "ice ball" at the tip of the needle. As the temperature drops, ice crystals form within the cancer cells, causing them to burst. The procedure typically involves several "freeze-thaw" cycles. The freezing ruptures the cell membranes, and the subsequent thawing further disrupts the cellular structure, ensuring the malignancy is neutralized.
Target Demographics
It is important to note that cryoablation is not currently a universal replacement for surgery. According to the Breast Cancer Research Foundation and recent FDA guidelines, the procedure is specifically indicated for:
- Patients with low-risk, early-stage breast cancer.
- Tumors that are hormone receptor-positive (HR+).
- Patients, often in older demographics, who may not be ideal candidates for general anesthesia or invasive surgery.
- Tumors that are typically smaller than 1.5 to 2 centimeters in diameter.
Chronology: From Experimental Trials to FDA Approval
The journey of cryoablation from an experimental concept to an FDA-cleared treatment has been decades in the making. While the use of cold to treat ailments dates back to ancient civilizations, its application in modern oncology began to gain traction in the late 20th century for prostate and liver cancers.
The 2009 Milestone
The modern era of breast cryoablation research hit a major milestone in 2009. Dr. Heather McArthur, M.D., M.P.H., a BCRF-supported researcher and clinical director of the Breast Cancer Program at UT Southwestern’s Simmons Comprehensive Cancer Center, began developing some of the first rigorous clinical trials for the technology.
"I’ve been using cryoablation since we developed our first trial in 2009," Dr. McArthur notes. These early studies were designed to determine if the procedure could not only kill the primary tumor but also trigger a systemic immune response.
The ICE 3 Trial
Between 2014 and 2021, the ICE 3 trial—the largest controlled study of its kind—monitored the efficacy of cryoablation in women aged 60 and older with low-risk, early-stage breast cancer. The results of this trial, published recently in the Annals of Surgical Oncology, provided the clinical bedrock for the treatment’s wider acceptance.
Recent FDA Clearance
Following the success of the ICE 3 data, the U.S. Food and Drug Administration (FDA) granted specific clearance for cryoablation systems to be used in the treatment of low-risk breast cancer. This approval was a watershed moment, moving the procedure from the realm of "experimental" to a recognized "standard of care" for specific patient profiles, provided it is used in conjunction with endocrine therapy.
Supporting Data: Efficacy and the Immune Response
The shift toward cryoablation is driven by data that proves it is not just a "gentler" option, but a highly effective one.
Success Rates and Recurrence
The ICE 3 trial results, published in 2024, provided compelling statistics for patients and providers:
- Recurrence Rate: The rate of tumor recurrence five years after the procedure was only 4.3%. This is comparable to the recurrence rates seen in traditional lumpectomies for similar low-risk profiles.
- Survival Rate: The breast cancer-specific survival rate for patients in the trial was 96.7%.
- Patient Comfort: In clinical trials, the vast majority of patients reported minimal pain. Dr. McArthur notes that out of all her trial patients, only one required Tylenol for post-procedural discomfort.
The "Vaccine" Effect: Cryo-Immunotherapy
Perhaps the most exciting data emerging from BCRF-supported research is the relationship between cryoablation and the immune system. When a tumor is removed surgically, it is taken out of the body entirely. However, when a tumor is frozen and left in place to be reabsorbed, it acts as a signaling flare for the immune system.
"This causes inflammation that brings the immune cells into the environment," Dr. McArthur explains. "It also physically disrupts tumors, breaking them down into smaller pieces that might be more easily digested by immune cells."
Dr. McArthur is currently researching a combination treatment that pairs cryoablation with checkpoint inhibitors—a form of immunotherapy. The goal is to use the frozen tumor debris to "train" the immune system to recognize cancer cells throughout the body. This creates a "vaccine-like" response that could potentially prevent the cancer from ever returning or spreading, a concept known as the abscopal effect.
Official Responses: Expert Insights and Regulatory Standing
The medical community’s response to cryoablation has been one of "cautious optimism," emphasizing that while the technology is revolutionary, patient selection is paramount.
The Physician’s Perspective
Dr. Heather McArthur emphasizes that cryoablation is an exercise in precision medicine. "It’s been shown to be an effective alternative to surgery in older populations that have hormone receptor-positive breast cancer," she states. She highlights that for many patients—particularly those for whom surgery poses a high risk due to age or other health conditions—cryoablation is a "terrific alternative."
The FDA’s Stance
The FDA’s approval comes with strict stipulations. The treatment is currently indicated for patients with "low-risk" profiles. Furthermore, the FDA mandates that these patients must also undergo endocrine (hormone) therapy as part of their treatment plan. This ensures that while the primary tumor is destroyed by cold, any remaining microscopic cells are suppressed by medication.
The Breast Cancer Research Foundation (BCRF)
The BCRF continues to fund research into cryoablation, viewing it as a critical component of the future of oncology. Their focus is on expanding the criteria for who can receive the treatment and perfecting the combination of freezing and immunotherapy to improve overall cure rates.
Implications: The Future of Breast Cancer Care
The rise of cryoablation signals a broader shift in how society views cancer treatment. We are moving away from the "maximum tolerated treatment" toward the "minimum effective treatment."
Psychological and Physical Impact
The implications for patient quality of life are profound. A traditional lumpectomy or mastectomy involves general anesthesia, surgical scars, potential changes in breast shape, and a recovery period that can last weeks.
In contrast, cryoablation is an outpatient procedure that takes approximately 30 minutes. Patients remain awake under local anesthesia, can often see the "ice ball" forming on a monitor, and can return home the same day with nothing more than a small bandage. The dead tumor cells are naturally cleared by the body’s white blood cells over several months, leaving no surgical scar and preserving the natural aesthetics of the breast.
Economic and Systemic Shifts
As an outpatient procedure, cryoablation has the potential to reduce healthcare costs by eliminating the need for operating rooms and hospital stays. It also opens doors for treatment in areas where access to full surgical suites may be limited.
The Road Ahead
While the current FDA approval is a major victory, the next decade of research will focus on whether cryoablation can be used for higher-risk patients or larger tumors. The ongoing trials involving checkpoint inhibitors will be the "next frontier," potentially turning a local treatment into a systemic shield against cancer.
As Dr. McArthur concludes, cryoablation "holds a lot of potential." It is a testament to how far cancer research has come—where the cold, once a symbol of stagnation, has become a powerful tool for healing and life.
Disclaimer: Cryoablation is not suitable for every breast cancer patient. If you or a loved one are considering this treatment, it is essential to consult with a multidisciplinary oncology team to determine if you meet the specific criteria for this procedure.
About the Author
